Zymeworks Inc.

Zymeworks is a clinical-stage biotechnology company unlocking new possibilities in cancer and autoimmune disease treatment. Our mission is to make a meaningful difference in the lives of patients by advancing a growing pipeline of next-generation antibody therapeutics, including T cell engagers and antibody-drug conjugates (ADCs). Our lead asset, zanidatamab—a HER2-targeted bispecific antibody— is partnered with Jazz Pharmaceuticals and BeOne Medicines and is approved in the U.S. and China for previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. We’re also rapidly advancing a robust pipeline of wholly-owned ADC and multispecific programs designed to target areas of significant unmet medical need. With integrated R&D capabilities and a proven track record of scientific innovation and collaboration, we’re building strategic partnerships and a culture where passionate people can make an impact. Join us as we engineer what’s next in biotherapeutics.